Clinical trial
A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From…
NCT00463021 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00463021 |
|---|---|
| Title | A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection |
| Official title | A Phase 4, Multi Center, Open-Label, Randomized Study to Determine Clinically Appropriate Doses of Hectorol® (Doxercalciferol Capsules) When Converting From Zemplar® (Paricalcitol Injection) for the Treatment of Secondary Hyperparathyroidism in Stage 5 Chronic Kidney Disease (CKD) Subjects on… |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Secondary Hyperparathyroidism |
| Intervention type | Drug |
| Interventions | Hectorol (doxercalciferol capsules), Zemplar (paricalcitol injection) |
| Enrollment | 36 |
| Start date | Apr 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Apr 19, 2007 |
| Last update posted | May 5, 2015 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: